Effectiveness
Both app-based treatment and care-as-usual showed improvements of all
symptom scores after 12 months (Supplemental table S3). Severity of
incontinence improved with respectively -2.17 (SD 2.8) versus -3.43 (SD
3.6) points, the change in condition-specific quality of life improved
with respectively -4.66 (SD 5.1) versus -4.34 (SD 5.7) and generic
quality of life improved with respectively 0.021 (SD 0.17) versus 0.0008
(SD 0.14) points. However, there were no statistically significant
differences in the change in symptom scores between treatment groups
(Supplemental table S4). After 12 months, women gained an average 0.71
IIALYs in the intervention group and 0.66 IIALYs in the
care-as-usualgroup (Table 2). In addition, women gained an average of
0.89 QALYs in the app-based treatment group and 0.91 QALYs in the
care-as-usualgroup, equating to respective gains of 0.89 and 0.91 years
in perfect (incontinence-specific) health.